Beam Therapeutics (BEAM) to Release Quarterly Earnings on Tuesday

by · The Cerbat Gem

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) is projected to post its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($1.03) per share and revenue of $12.8250 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.04. Beam Therapeutics had a negative return on equity of 43.15% and a negative net margin of 661.31%.The company had revenue of $8.47 million during the quarter, compared to the consensus estimate of $13.29 million. During the same period last year, the company earned ($1.11) earnings per share. The firm’s revenue was down 28.0% compared to the same quarter last year. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Price Performance

Shares of BEAM stock opened at $25.01 on Friday. The stock has a market capitalization of $2.53 billion, a PE ratio of -5.56 and a beta of 2.25. The business’s 50 day simple moving average is $23.34 and its 200 day simple moving average is $20.07. Beam Therapeutics has a one year low of $13.52 and a one year high of $35.25.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Beam Therapeutics from $48.00 to $46.00 and set an “overweight” rating on the stock in a research note on Thursday, October 9th. Barclays dropped their target price on shares of Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald upgraded Beam Therapeutics to a “strong-buy” rating in a report on Monday, July 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group assumed coverage on Beam Therapeutics in a research report on Thursday, October 9th. They set a “buy” rating and a $41.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Beam Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $45.92.

Read Our Latest Report on BEAM

Hedge Funds Weigh In On Beam Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. boosted its stake in Beam Therapeutics by 46.0% in the second quarter. Invesco Ltd. now owns 128,874 shares of the company’s stock valued at $2,192,000 after acquiring an additional 40,583 shares during the last quarter. Rafferty Asset Management LLC raised its holdings in shares of Beam Therapeutics by 2.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 122,832 shares of the company’s stock worth $2,089,000 after purchasing an additional 2,961 shares during the period. Hudson Bay Capital Management LP purchased a new position in Beam Therapeutics in the second quarter valued at approximately $765,000. Jones Financial Companies Lllp grew its holdings in Beam Therapeutics by 55,780.0% during the first quarter. Jones Financial Companies Lllp now owns 33,528 shares of the company’s stock valued at $655,000 after purchasing an additional 33,468 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Beam Therapeutics by 113.3% in the second quarter. Tower Research Capital LLC TRC now owns 31,888 shares of the company’s stock worth $542,000 after buying an additional 16,935 shares during the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

Beam Therapeutics Company Profile

(Get Free Report)

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Featured Articles